Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Discovery of a cofactor-independent inhibitor of Mycobacterium tuberculosis InhA.

Xia Y, Zhou Y, Carter DS, McNeil MB, Choi W, Halladay J, Berry PW, Mao W, Hernandez V, O'Malley T, Korkegian A, Sunde B, Flint L, Woolhiser LK, Scherman MS, Gruppo V, Hastings C, Robertson GT, Ioerger TR, Sacchettini J, Tonge PJ, Lenaerts AJ, Parish T, Alley M.

Life Sci Alliance. 2018 Jun 1;1(3):e201800025. doi: 10.26508/lsa.201800025. eCollection 2018 Jun.

2.

Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA Synthetase.

Palencia A, Li X, Bu W, Choi W, Ding CZ, Easom EE, Feng L, Hernandez V, Houston P, Liu L, Meewan M, Mohan M, Rock FL, Sexton H, Zhang S, Zhou Y, Wan B, Wang Y, Franzblau SG, Woolhiser L, Gruppo V, Lenaerts AJ, O'Malley T, Parish T, Cooper CB, Waters MG, Ma Z, Ioerger TR, Sacchettini JC, Rullas J, Angulo-Barturen I, Pérez-Herrán E, Mendoza A, Barros D, Cusack S, Plattner JJ, Alley MR.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6271-80. doi: 10.1128/AAC.01339-16. Print 2016 Oct.

3.

Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas.

Irwin SM, Gruppo V, Brooks E, Gilliland J, Scherman M, Reichlen MJ, Leistikow R, Kramnik I, Nuermberger EL, Voskuil MI, Lenaerts AJ.

Antimicrob Agents Chemother. 2014 Jul;58(7):4026-34. doi: 10.1128/AAC.02565-14. Epub 2014 May 5.

4.

In vivo/in vitro pharmacokinetic and pharmacodynamic study of spray-dried poly-(dl-lactic-co-glycolic) acid nanoparticles encapsulating rifampicin and isoniazid.

Booysen LL, Kalombo L, Brooks E, Hansen R, Gilliland J, Gruppo V, Lungenhofer P, Semete-Makokotlela B, Swai HS, Kotze AF, Lenaerts A, du Plessis LH.

Int J Pharm. 2013 Feb 28;444(1-2):10-7. doi: 10.1016/j.ijpharm.2013.01.038. Epub 2013 Jan 26.

PMID:
23357255
5.

Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties.

Rakesh, Bruhn D, Madhura DB, Maddox M, Lee RB, Trivedi A, Yang L, Scherman MS, Gilliland JC, Gruppo V, McNeil MR, Lenaerts AJ, Meibohm B, Lee RE.

Bioorg Med Chem. 2012 Oct 15;20(20):6063-72. doi: 10.1016/j.bmc.2012.08.023. Epub 2012 Aug 28.

6.

Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane.

Grzegorzewicz AE, Pham H, Gundi VA, Scherman MS, North EJ, Hess T, Jones V, Gruppo V, Born SE, Korduláková J, Chavadi SS, Morisseau C, Lenaerts AJ, Lee RE, McNeil MR, Jackson M.

Nat Chem Biol. 2012 Feb 19;8(4):334-41. doi: 10.1038/nchembio.794.

7.

Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis.

De Groote MA, Gruppo V, Woolhiser LK, Orme IM, Gilliland JC, Lenaerts AJ.

Antimicrob Agents Chemother. 2012 Feb;56(2):731-8. doi: 10.1128/AAC.05701-11. Epub 2011 Dec 5.

8.

Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.

De Groote MA, Gilliland JC, Wells CL, Brooks EJ, Woolhiser LK, Gruppo V, Peloquin CA, Orme IM, Lenaerts AJ.

Antimicrob Agents Chemother. 2011 Mar;55(3):1237-47. doi: 10.1128/AAC.00595-10. Epub 2010 Dec 6.

9.

The DosR regulon of M. tuberculosis and antibacterial tolerance.

Bartek IL, Rutherford R, Gruppo V, Morton RA, Morris RP, Klein MR, Visconti KC, Ryan GJ, Schoolnik GK, Lenaerts A, Voskuil MI.

Tuberculosis (Edinb). 2009 Jul;89(4):310-6. doi: 10.1016/j.tube.2009.06.001. Epub 2009 Jul 3.

10.

Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo.

Lenaerts AJ, Bitting C, Woolhiser L, Gruppo V, Marietta KS, Johnson CM, Orme IM.

Antimicrob Agents Chemother. 2008 Apr;52(4):1513-5. doi: 10.1128/AAC.00897-07. Epub 2008 Feb 11.

11.

Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis: evaluation of A-ring-modified diphenyl ethers as high-affinity InhA inhibitors.

Boyne ME, Sullivan TJ, amEnde CW, Lu H, Gruppo V, Heaslip D, Amin AG, Chatterjee D, Lenaerts A, Tonge PJ, Slayden RA.

Antimicrob Agents Chemother. 2007 Oct;51(10):3562-7. Epub 2007 Jul 30.

12.

In vivo adaptation of the Wayne model of latent tuberculosis.

Woolhiser L, Tamayo MH, Wang B, Gruppo V, Belisle JT, Lenaerts AJ, Basaraba RJ, Orme IM.

Infect Immun. 2007 May;75(5):2621-5. Epub 2007 Feb 5.

13.

Mycobacteria lacking the RD1 region do not induce necrosis in the lungs of mice lacking interferon-gamma.

Junqueira-Kipnis AP, Basaraba RJ, Gruppo V, Palanisamy G, Turner OC, Hsu T, Jacobs WR Jr, Fulton SA, Reba SM, Boom WH, Orme IM.

Immunology. 2006 Oct;119(2):224-31.

14.

Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis.

Gruppo V, Johnson CM, Marietta KS, Scherman H, Zink EE, Crick DC, Adams LB, Orme IM, Lenaerts AJ.

Antimicrob Agents Chemother. 2006 Apr;50(4):1245-50.

15.

Significant increases in the levels of liver enzymes in mice treated with anti-tuberculosis drugs.

Lenaerts AJ, Johnson CM, Marrieta KS, Gruppo V, Orme IM.

Int J Antimicrob Agents. 2005 Aug;26(2):152-8.

PMID:
15953708
16.

Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.

Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, Tompkins NM, Rose JD, Reynolds RC, Orme IM.

Antimicrob Agents Chemother. 2005 Jun;49(6):2294-301.

17.

The principal sigma factor sigA mediates enhanced growth of Mycobacterium tuberculosis in vivo.

Wu S, Howard ST, Lakey DL, Kipnis A, Samten B, Safi H, Gruppo V, Wizel B, Shams H, Basaraba RJ, Orme IM, Barnes PF.

Mol Microbiol. 2004 Mar;51(6):1551-62.

19.

Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice.

Lenaerts AJ, Gruppo V, Brooks JV, Orme IM.

Antimicrob Agents Chemother. 2003 Feb;47(2):783-5.

20.

Supplemental Content

Loading ...
Support Center